Trial reportMenopause (New York, N.Y.)2018
Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis.
Trial report in Menopause (New York, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05346419 (Risedronate With High-dose Vitamin D Resolves Hyperparathyroidism and Hypovitaminosis D But Not Osteoporosis in Mexican Postmenopausal Patients), which is not on this map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Risedronate With High-dose Vitamin D Resolves Hyperparathyroidism and Hypovitaminosis D But Not Osteoporosis in Mexican Postmenopausal Patients
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of postmenopausal osteoporosis: a systematic review and Bayesian network meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.BMJ (Clinical research ed.) · 2023Pooled it
- Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis.Journal of orthopaedic surgery and research · 2023Pooled it
- Fractures reduction with osteoporotic treatments in patients over 75-year-old: A systematic review and meta-analysis.Frontiers in aging · 2022Pooled it
- Advancing care: optimizing osteoporosis treatment in the older and oldest old population.Aging clinical and experimental research · 2025Review
- Review
- The Sequential Therapy in Osteoporosis.Indian journal of orthopaedics · 2023Review
- Hormones and Aging: An Endocrine Society Scientific Statement.The Journal of clinical endocrinology and metabolism · 2023Article
- Advancement in the Treatment of Osteoporosis and the Effects on Bone Healing.Journal of clinical medicine · 2022Review
- The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence.Archives of endocrinology and metabolism · 2022Review
- Skeletal Aging.Mayo Clinic proceedings · 2022Review
- The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density.Drugs · 2021Review
- Pharmacologic Interventions for Fracture Risk Reduction in the Oldest Old: What Is the Evidence?JBMR plus · 2021Article
- Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?Current osteoporosis reports · 2021Review
- Abaloparatide and the Spine: A Narrative Review.Clinical interventions in aging · 2020Review
- Physiological roles of parathyroid hormone-related protein.Acta bio-medica : Atenei Parmensis · 2019Review
- Regulation of Skeletal Homeostasis.Endocrine reviews · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
Abstract
objectiveAdvanced age is an important risk factor for fracture. The Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) trial showed that subcutaneous abaloparatide increased bone mineral density (BMD) and reduced the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. This study describes the effects of abaloparatide in the subgroup of women aged 80 or more years in ACTIVE.
methodsPost hoc analyses of BMD and fracture incidence in this subgroup of women who received abaloparatide or placebo in the 18-month, phase 3, double-blind, randomized controlled ACTIVE trial.
resultsThe mean ages of the women ≥80 years were 81.9 and 81.7 years in the placebo (n = 43) and abaloparatide (n = 51) groups, respectively. The increases in BMD from baseline to 18 months with abaloparatide treatment were 3.9% at the total hip (P < 0.001), 3.6% at the femoral neck (P < 0.01), and 12.1% at the lumbar spine (P < 0.001), and were similar to those observed in the overall population. Abaloparatide therapy was associated with numerical, but not statistically significant, reductions in the risk of vertebral and nonvertebral fractures in this subpopulation, compared with placebo. The proportion of participants reporting adverse events was similar between treatment groups and between the older subgroup and the overall population.
conclusionAbaloparatide was effective in increasing BMD in the very elderly subgroup of ACTIVE, with a safety profile similar to that of the overall study population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.